6 citations
,
July 2024 in “The Journal of the American Board of Family Medicine” GPT-4 performs well on medical exams but still needs human doctors for critical thinking.
January 2022 in “Drugs of Today”
2 citations
,
April 2019 in “Journal of the American Society of Nephrology” Fluconazole might be a new treatment for a type of diabetes that affects water balance in the body.
5 citations
,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
5 citations
,
December 2022 in “Annals Academy of Medicine Singapore” Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
47 citations
,
November 1982 in “Journal of Cardiovascular Pharmacology” Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
3 citations
,
December 2023 in “International Journal of Nanomedicine” Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.
May 2021 in “Letters in Applied NanoBioScience” Pranlukast and mirabegron may work as new diabetes drugs.
1 citations
,
May 2023 in “Elsevier eBooks”
Different oral anticoagulants cause various non-bleeding side effects, so careful monitoring is needed.
25 citations
,
October 2018 in “Journal of Mind and Medical Sciences” New oral anticoagulants are safer and easier to use with new reversal agents for bleeding emergencies.
June 2023 in “Frontiers in Cardiovascular Medicine” Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
May 2024 in “Reactions weekly” 6 citations
,
March 2023 in “Frontiers in Cellular and Infection Microbiology” Golvatinib shows promise as a treatment for Omicron in elderly patients.
March 2005 in “Inpharma Weekly” China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.
1 citations
,
October 2011 in “Hospital Pharmacy”
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
2 citations
,
November 2024 in “AAPS PharmSciTech” Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.
June 2026 in “International Journal of Drug Delivery Technology” Fast-dissolving nifedipine tablets were successfully developed for better oral delivery.
40 citations
,
July 2011 in “The journal of clinical hypertension” Hydralazine and minoxidil are blood pressure medications that relax blood vessels, with potential side effects like rapid heartbeat and fluid retention, and are used for severe or pregnancy-related hypertension.
March 2026 in “Korean Journal of Clinical Pharmacy” In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
January 2025 in “Drug repurposing” New drug uses show promise but need more research.
July 2024 in “Reactions Weekly”